keyword
MENU ▼
Read by QxMD icon Read
search

Cardiovascular risk reduction

keyword
https://www.readbyqxmd.com/read/28110297/the-technical-report-on-sodium-intake-and-cardiovascular-disease-in-low-and-middle-income-countries-by-the-joint-working-group-of-the-world-heart-federation-the-european-society-of-hypertension-and-the-european-public-health-association
#1
REVIEW
Giuseppe Mancia, Suzanne Oparil, Paul K Whelton, Martin McKee, Anna Dominiczak, Friedrich C Luft, Khalid AlHabib, Fernando Lanas, Albertino Damasceno, Dorairaj Prabhakaran, Giuseppe La Torre, Michael Weber, Martin O'Donnell, Sidney C Smith, Jagat Narula
Ingestion of sodium is essential to health, but excess sodium intake is a risk factor for hypertension and cardiovascular disease. Defining an optimal range of sodium intake in populations has been challenging and controversial. Clinical trials evaluating the effect of sodium reduction on blood pressure have shown blood pressure lowering effects down to sodium intake of less than 1.5 g/day. Findings from these blood pressure trials form the basis for current guideline recommendations to reduce sodium intake to less than 2...
January 21, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28109182/are-home-visits-an-effective-method-for-diabetes-management-a-quantitative-systematic-review-and-meta-analysis
#2
Lin Han, Yuxia Ma, Suhong Wei, Jinhui Tian, Xiaochun Yang, Xiping Shen, Jun Zhang, Yuexian Shi
AIMS: Previous reviews have revealed uncertainty regarding the effectiveness of home visit interventions for managing diabetes. Therefore, we performed a quantitative systematic review and meta-analysis to evaluate the effects of home visit interventions among patients with diabetes. METHODS: We searched various electronic databases (PubMed, EMBASE, Cochrane Library, Web of Science, CINAHL, Wanfang, and Chinese scientific full-text databases) from their inception until March 2016...
January 21, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/28109003/eradication-of-hcv-and-non-liver-related-non-aids-related-events-in-hiv-hcv-coinfection
#3
Juan Berenguer, Elena Rodríguez-Castellano, Ana Carrero, Miguel A Von Wichmann, Marta Montero, María J Galindo, Josep Mallolas, Manuel Crespo, María J Téllez, Carmen Quereda, José Sanz, Carlos Barros, Cristina Tural, Ignacio Santos, Federico Pulido, Josep M Guardiola, Rafael Rubio, Enrique Ortega, María L Montes, Juan J Jusdado, Gabriel Gaspar, Herminia Esteban, José M Bellón, Juan González-García
: We assessed non-liver-related non-AIDS-related (NLR-NAR) events and mortality in a cohort of HIV/HCV-coinfected patients treated with interferon and ribavirin between 2000 and 2008. The censoring date was May 31, 2014. Cox regression analysis was performed to assess the adjusted hazard rate (HR) of overall death in responders and non-responders. Fine and Gray regression analysis was conducted to determine the adjusted sub-hazard rate (sHR) of NLR deaths and NLR-NAR events considering death as the competing risk...
January 21, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28107561/beta-blockers-for-hypertension
#4
REVIEW
Charles S Wiysonge, Hazel A Bradley, Jimmy Volmink, Bongani M Mayosi, Lionel H Opie
BACKGROUND: Beta-blockers refer to a mixed group of drugs with diverse pharmacodynamic and pharmacokinetic properties. They have shown long-term beneficial effects on mortality and cardiovascular disease (CVD) when used in people with heart failure or acute myocardial infarction. Beta-blockers were thought to have similar beneficial effects when used as first-line therapy for hypertension. However, the benefit of beta-blockers as first-line therapy for hypertension without compelling indications is controversial...
January 20, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28106149/blood-pressure-reduction-in-diabetes-lessons-from-accord-sprint-and-empa-reg-outcome
#5
REVIEW
Pantelis A Sarafidis, Antonios A Lazaridis, Gema Ruiz-Hurtado, Luis M Ruilope
In patients with diabetes mellitus, the presence of hypertension substantially increases the risk of cardiovascular events, and reductions in blood pressure (BP) can reduce cardiovascular morbidity and mortality. Following evidence from trials randomizing patients to diastolic BP levels, previous guidelines recommended an office BP target of <130/80 mmHg in individuals with diabetes mellitus. However, the evidence for this systolic BP (SBP) target was derived from observational studies. When the results of the ACCORD-BP study showed that those individuals with diabetes mellitus and a target BP of <120 mmHg had a cardiovascular risk that is similar to those with <140 mmHg, all guidelines returned to a recommended SBP of <140 mmHg...
January 20, 2017: Nature Reviews. Endocrinology
https://www.readbyqxmd.com/read/28105731/liraglutide-effects-on-cardiovascular-risk-biomarkers-in-patients-with-type-2-diabetes-and-albuminuria-a-sub-analysis-of-a-randomised-placebo-controlled-double-blind-cross-over-trial
#6
Bernt Johan von Scholten, Frederik Persson, Signe Rosenlund, Jesper Eugen-Olsen, Tomasz Pielak, Jens Faber, Tine Willum Hansen, Peter Rossing
: We assessed the effects of liraglutide treatment on five cardiovascular risk biomarkers, reflecting different pathophysiology: 1) Tumour necrosis factor-alpha (TNF-alpha); 2) Soluble urokinase plasminogen activator receptor (suPAR); 3) Mid-regional pro-adrenomedullin (MR-proADM); 4) Mid-regional pro-atrial natriuretic peptide (MR-proANP); and 5) Copeptin, in type 2 diabetes patients with albuminuria. In a randomised, double-blind, placebo-controlled, cross-over trial we enrolled patients with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio (UACR) > 30 mg/g) and estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1...
January 20, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28105515/changes-in-brain-natriuretic-peptide-in-chronic-heart-failure-patients-treated-with-long-acting-versus-short-acting-loop-diuretics-j-melodic-subanalysis
#7
Miho Fukui, Takeshi Tsujino, Shinichi Hirotani, Hiroshi Ito, Kazuhiro Yamamoto, Takashi Akasaka, Yutaka Hirano, Nobuyuki Ohte, Takashi Daimon, Satoshi Nakatani, Masaaki Kawabata, Tohru Masuyama
We have previously reported that a long-acting loop diuretic, azosemide, reduces cardiovascular risks in patients with chronic heart failure (CHF) as compared with a short-acting one, furosemide, in Japanese Multicenter Evaluation of LOng- versus short-acting Diuretics In Congestive heart failure (J-MELODIC). However, the mechanisms of the difference have not been elucidated. This study aimed to examine whether there is a difference in the reduction in plasma brain natriuretic peptide (BNP) level and in left ventricular (LV) functional recovery between the CHF patients treated with the long-acting diuretic (the azosemide group) and the short-acting diuretic (the furosemide group)...
January 19, 2017: Heart and Vessels
https://www.readbyqxmd.com/read/28103812/can-coefficient-of-variation-of-time-domain-analysis-be-valuable-for-detecting-cardiovascular-autonomic-neuropathy-in-young-patients-with-type-1-diabetes-a-case-control-study
#8
Dovile Razanskaite-Virbickiene, Evalda Danyte, Giedre Mockeviciene, Rimante Dobrovolskiene, Rasa Verkauskiene, Rimantas Zalinkevicius
BACKGROUND: Cardiovascular autonomic neuropathy (CAN) increases morbidity and mortality in diabetes through association with a high risk of cardiac arrhythmias and sudden death, possibly related to silent myocardial ischemia. During the sub-clinical stage, CAN can be detected through reduction in heart rate variability (HRV). The aim of our study was to estimate if the time and frequency-domain analysis can be valuable for detecting CAN in young patients with type 1 diabetes mellitus (T1DM)...
January 19, 2017: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/28102731/microfluidic-whole-blood-testing-of-platelet-response-to-pharmacological-agents
#9
Ruizhi Li, Tilo Grosser, Scott L Diamond
Platelets present a number of intracellular and transmembrane targets subject to pharmacological modulation, either for cardiovascular disease reduction or as an unintended drug response. Microfluidic devices allow human blood to clot on a defined surface under controlled hemodynamic and pharmacological conditions. The potencies of a number of antiplatelet and anticancer drugs have been tested with respect to platelet deposition on collagen under flow. Inhibitors of cyclooxygenase-1 (COX-1) reduce platelet deposition, either when added ex vivo to blood or ingested orally by patients prior to testing...
January 19, 2017: Platelets
https://www.readbyqxmd.com/read/28102030/impact-of-sodium-glucose-cotransporter-2-inhibitors-on-nonglycemic-outcomes-in-patients-with-type-2-diabetes
#10
Jennifer M Trujillo, Wesley A Nuffer
The efficacy of the sodium-glucose cotransporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, and empagliflozin in reducing hyperglycemia in patients with type 2 diabetes is well documented. In addition, positive effects have been observed with these agents on nonglycemic variables, such as reductions in body weight and blood pressure, which may confer additional health benefits. SGLT2 inhibitors are also associated with evidence of renal-protecting benefits. Furthermore, during the landmark Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial, a substantial reduction in major adverse cardiovascular outcomes was demonstrated with empagliflozin therapy...
January 19, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28101564/changes-in-body-composition-after-spasticity-treatment-with-intrathecal-baclofen
#11
Olle Skogberg, Kersti Samuelsson, Per Ertzgaard, Richard Levi
OBJECTIVE: To assess changes in body composition, body weight and resting metabolic rate in patients who received intrathecal baclofen therapy for spasticity. DESIGN: Prospective, longitudinal, quasi-experimental, with a pre/post design. PATIENTS: Twelve patients with spasticity, fulfilling study criteria, and due for pump implantation for intrathecal baclofen therapy, completed the study. METHODS: Data were obtained before, 6 months and 12 months after commencement of intrathecal baclofen therapy as regards body composition (by skinfold calliper), body weight, and resting metabolic rate (by resting oxygen consumption)...
January 19, 2017: Journal of Rehabilitation Medicine
https://www.readbyqxmd.com/read/28100921/clinical-significance-of-cardiometabolic-memory-a-systematic-review-of-randomized-controlled-trials
#12
REVIEW
Hiroshi Itoh, Isao Kurihara, Kazutoshi Miyashita, Masami Tanaka
'Cardiometabolic memory' has been proposed based on clinical evidence to explain how, even after the cessation of a clinical trial, the superiority of one treatment over the outcome persists. To understand the cardiometabolic memory phenomenon, we performed a systematic review of randomized controlled trials (RCTs) using PubMed in August 2016. The search terms 'randomized controlled trial', 'post-trial follow-up' and 'diabetes, hypertension or dyslipidemia' were used, and articles published after the year 2000 were searched...
January 19, 2017: Hypertension Research: Official Journal of the Japanese Society of Hypertension
https://www.readbyqxmd.com/read/28100880/significant-association-of-serum-adiponectin-and-creatine-kinase-mb-levels-in-st-segment-elevation-myocardial-infarction
#13
Tomoaki Natsukawa, Norikazu Maeda, Shiro Fukuda, Masaya Yamaoka, Yuya Fujishima, Hirofumi Nagao, Fumi Sato, Hitoshi Nishizawa, Hirotaka Sawano, Yasuyuki Hayashi, Tohru Funahashi, Tatsuro Kai, Iichiro Shimomura
AIMS: Adiponectin, an adipocyte-specific secretory protein, abundantly exists in the blood stream while its concentration paradoxically decreases in obesity. Hypoadiponectinemia is one of risks of cardiovascular diseases. However, impact of serum adiponectin concentration on acute ischemic myocardial damages has not been fully clarified. The present study investigated the association of serum adiponectin and creatine kinase (CK)-MB levels in subjects with ST-segment elevation myocardial infarction (STEMI)...
January 17, 2017: Journal of Atherosclerosis and Thrombosis
https://www.readbyqxmd.com/read/28100284/role-of-flavonoids-and-nitrates-in-cardiovascular-health
#14
Julie A Lovegrove, Alex Stainer, Ditte A Hobbs
CVD remain the leading cause of death globally. Effective dietary strategies for their reduction are of high priority. Increasing evidence suggests that phytochemicals, particularly dietary flavonoids and nitrates, are key modulators of CVD risk reduction through impact on multiple risk factors. The aim of this review is to explore the evidence for the impact of flavonoid- and nitrate-rich foods and supplements on CVD risk, with specific reference to their importance as mediators of vascular health and platelet function...
January 19, 2017: Proceedings of the Nutrition Society
https://www.readbyqxmd.com/read/28099783/ketosis-and-diabetic-ketoacidosis-in-response-to-sglt2-inhibitors-basic-mechanisms-and-therapeutic-perspectives
#15
REVIEW
Hongyu Qiu, Aleksandra Novikov, Volker Vallon
Inhibitors of the sodium-glucose cotransporter SGLT2 are a new class of anti-hyperglycemic drugs that have been approved for the treatment of type 2 diabetes mellitus (T2DM). These drugs inhibit glucose reabsorption in the proximal tubules of the kidney thereby enhancing glucosuria and lowering blood glucose levels. Additional consequences and benefits include a reduction in body weight, uric acid levels, and blood pressure. Moreover, SGLT2 inhibition can have protective effects on the kidney and cardiovascular system in patients with T2DM and high cardiovascular risk...
January 18, 2017: Diabetes/metabolism Research and Reviews
https://www.readbyqxmd.com/read/28099551/cholesterol-and-prevention-of-atherosclerotic-events-limits-of-a-new-frontier
#16
Luís Eduardo Teixeira de Macedo, Faerstein E
Control of atherosclerotic cardiovascular disease - a highly prevalent condition and one of the main causes of mortality in Brazil and worldwide - is a recurrent subject of great interest for public health. Recently, three new guidelines on dyslipidemia and atherosclerosis prevention have been published. The close release of these important publications is a good opportunity for comparison: the Brazilian model has greater sensitivity, the English model does not work with risk stratification, and the American model may be overestimating the risk...
January 12, 2017: Revista de Saúde Pública
https://www.readbyqxmd.com/read/28099403/outcome-of-liver-transplant-recipients-with-revascularized-coronary-artery-disease-a-comparative-analysis-with-and-without-cardiovascular-risk-factors
#17
Sanjaya K Satapathy, Jason M Vanatta, Ryan Helmick, Albert Flowers, Satish K Kedia, Yu Jiang, Bilal Ali, James Eason, Satheesh P Nair, Uzoma N Ibebuogu
BACKGROUND: Coronary artery disease (CAD) is a significant problem during evaluation for liver transplantation (LT). We aim to assess survival in LT recipients based on presence, severity, extent of CAD and cardiac events within 90 days of LT. METHODS: 87 LT recipients with history of pre-LT angiogram (12/2005-12/2012) were compared with 2 control groups without prior angiogram, 72 LT recipients matched for cardiovascular risk factors (Control Gr I), and 119 consecutive LT recipients without any CV risk factors (Control Gr II)...
January 17, 2017: Transplantation
https://www.readbyqxmd.com/read/28099220/evacetrapib-another-cetp-inhibitor-for-dyslipidemia-with-no-clinical-benefit
#18
Vaughn A Eyvazian, William H Frishman
Evacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor that has been recently studied as a cholesterol modifying agent to reduce cardiovascular risk and mortality in high risk cardiovascular disease patients. Evacetrapib acts to decrease lipid exchange through CETP inhibition. CETP acts to transfer cholesteryl esters from high-density lipoprotein cholesterol (HDL-C) to low-density lipoprotein cholesterol (LDL-C) and very low-density lipoprotein cholesterol (VLDL-C). HDL-C is involved in reverse cholesterol transport and its blood levels have been shown to be inversely correlated with cardiovascular risk...
January 11, 2017: Cardiology in Review
https://www.readbyqxmd.com/read/28097904/estimated-burden-of-cardiovascular-disease-and-value-based-price-range-for-evolocumab-in-a-high-risk-secondary-prevention-population-in-the-us-payer-context
#19
Peter P Toth, Mark Danese, Guillermo Villa, Yi Qian, Anne Beaubrun, Armando Lira, Jeroen P Jansen
AIM: To estimate real-world cardiovascular disease (CVD) burden and value-based price range of evolocumab for a US-context, high-risk, secondary-prevention population. MATERIALS AND METHODS: Burden of CVD was assessed using the UK-based Clinical Practice Research Datalink (CPRD) in order to capture complete CV burden including CV mortality. Patients on standard of care (SOC; high-intensity statins) in CPRD were selected based on eligibility criteria of FOURIER, a phase 3 CV outcomes trial of evolocumab, and categorized into 4 cohorts: high-risk prevalent atherosclerotic CVD (ASCVD) cohort (N = 1448), acute coronary syndrome (ACS) (N = 602), ischemic stroke (IS) (N = 151), and heart failure (HF) (N = 291) incident cohorts...
January 18, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28096572/current-and-emerging-treatments-for-hypercholesterolemia-a-focus-on-statins-and-proprotein-convertase-subtilisin-kexin-type-9-inhibitors-for-perioperative-clinicians
#20
REVIEW
Terrence L Trentman, Steven G Avey, Harish Ramakrishna
Statins are a mainstay of hyperlipidemia treatment. These drugs inhibit the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase and have beneficial effects on atherosclerosis including plaque stabilization, reduction of platelet activation, and reduction of plaque proliferation and inflammation. Statins also have a benefit beyond atherosclerotic plaque, including anticoagulation, vasodilatation, antioxidant effects, and reduction of mediators of inflammation. In the perioperative period, statins appear to contribute to improved outcomes via these mechanisms...
October 2016: Journal of Anaesthesiology, Clinical Pharmacology
keyword
keyword
7995
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"